170 related articles for article (PubMed ID: 25600037)
1. [New SGLT2 inhibitor empagliflozin: modern and safe treatment of diabetes].
Rušavý Z
Vnitr Lek; 2014 Nov; 60(11):926-7, 929-30. PubMed ID: 25600037
[TBL] [Abstract][Full Text] [Related]
2. [Will the new SGLT2 inhibitor empagliflozin help us reduce the risk of hypoglycemia?].
Pelikánová T
Vnitr Lek; 2014 Dec; 60(12):1102, 1104-8. PubMed ID: 25692841
[TBL] [Abstract][Full Text] [Related]
3. [Empagliflozin - the new representative of SGLT2 transporter inhibitors for the treatment of patients with diabetes 2 type].
Prázný M; Slíva J
Vnitr Lek; 2015 Feb; 61(2):175-8. PubMed ID: 25813264
[TBL] [Abstract][Full Text] [Related]
4. Empagliflozin: a new treatment option for patients with type 2 diabetes mellitus.
Dailey GE
Drugs Today (Barc); 2015 Sep; 51(9):519-35. PubMed ID: 26488032
[TBL] [Abstract][Full Text] [Related]
5. Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus.
Triplitt C; Solis-Herrera C; Cersosimo E; Abdul-Ghani M; Defronzo RA
Expert Opin Pharmacother; 2015; 16(18):2819-33. PubMed ID: 26583910
[TBL] [Abstract][Full Text] [Related]
6. Empagliflozin: a sodium-glucose cotransporter 2 inhibitor for treatment of type 2 diabetes.
Dixit D; Yoon Y; Volino LR; Mansukhani RP
Am J Health Syst Pharm; 2015 Nov; 72(22):1943-54. PubMed ID: 26541949
[TBL] [Abstract][Full Text] [Related]
7. Empagliflozin, an SGLT2 inhibitor for the treatment of type 2 diabetes mellitus: a review of the evidence.
White JR
Ann Pharmacother; 2015 May; 49(5):582-98. PubMed ID: 25712444
[TBL] [Abstract][Full Text] [Related]
8. Pooled Safety and Tolerability Analysis of Empagliflozin in Patients with Type 2 Diabetes Mellitus.
Kinduryte Schorling O; Clark D; Zwiener I; Kaspers S; Lee J; Iliev H
Adv Ther; 2020 Aug; 37(8):3463-3484. PubMed ID: 32372290
[TBL] [Abstract][Full Text] [Related]
9. Empagliflozin: A Review in Type 2 Diabetes.
Frampton JE
Drugs; 2018 Jul; 78(10):1037-1048. PubMed ID: 29946963
[TBL] [Abstract][Full Text] [Related]
10. Empagliflozin for the treatment of type 2 diabetes.
Jahagirdar V; Barnett AH
Expert Opin Pharmacother; 2014 Nov; 15(16):2429-41. PubMed ID: 25301180
[TBL] [Abstract][Full Text] [Related]
11. [Empagliflozin: another of silent revolutioners].
Kvapil M
Vnitr Lek; 2014 Nov; 60(11):924-5. PubMed ID: 25612346
[No Abstract] [Full Text] [Related]
12. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial.
Kovacs CS; Seshiah V; Swallow R; Jones R; Rattunde H; Woerle HJ; Broedl UC;
Diabetes Obes Metab; 2014 Feb; 16(2):147-58. PubMed ID: 23906415
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis.
Liakos A; Karagiannis T; Athanasiadou E; Sarigianni M; Mainou M; Papatheodorou K; Bekiari E; Tsapas A
Diabetes Obes Metab; 2014 Oct; 16(10):984-93. PubMed ID: 24766495
[TBL] [Abstract][Full Text] [Related]
14. Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes: Pooled Analysis of Phase I-III Clinical Trials.
Kohler S; Zeller C; Iliev H; Kaspers S
Adv Ther; 2017 Jul; 34(7):1707-1726. PubMed ID: 28631216
[TBL] [Abstract][Full Text] [Related]
15. Exposure-response modelling for empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in patients with type 2 diabetes.
Riggs MM; Seman LJ; Staab A; MacGregor TR; Gillespie W; Gastonguay MR; Woerle HJ; Macha S
Br J Clin Pharmacol; 2014 Dec; 78(6):1407-18. PubMed ID: 24964723
[TBL] [Abstract][Full Text] [Related]
16. Combination therapy for patients with uncontrolled type 2 diabetes mellitus: adding empagliflozin to pioglitazone or pioglitazone plus metformin.
Blevins T
Expert Opin Drug Saf; 2015 May; 14(5):789-93. PubMed ID: 25789798
[TBL] [Abstract][Full Text] [Related]
17. Empagliflozin for the treatment of Type 2 diabetes.
Gangadharan Komala M; Mather A
Expert Rev Clin Pharmacol; 2014 May; 7(3):271-9. PubMed ID: 24716752
[TBL] [Abstract][Full Text] [Related]
18. Study rationale and design of the EANITIATE study (EmpAgliflozin compared to NPH Insulin for sTeroId diAbeTEs) - a randomized, controlled, multicenter trial of safety and efficacy of treatment with empagliflozin compared with NPH-insulin in patients with newly onset diabetes following initiation of glucocorticoid treatment.
Klarskov CK; Holm Schultz H; Persson F; Møller Christensen T; Almdal TP; Snorgaard O; Bagge Hansen K; Pedersen-Bjergaard U; Lommer Kristensen P
BMC Endocr Disord; 2020 Jun; 20(1):86. PubMed ID: 32539810
[TBL] [Abstract][Full Text] [Related]
19. Single-pill combination therapy for type 2 diabetes mellitus: linagliptin plus empagliflozin.
Aronson R
Curr Med Res Opin; 2015 May; 31(5):901-11. PubMed ID: 25775379
[TBL] [Abstract][Full Text] [Related]
20. The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension.
Gembardt F; Bartaun C; Jarzebska N; Mayoux E; Todorov VT; Hohenstein B; Hugo C
Am J Physiol Renal Physiol; 2014 Aug; 307(3):F317-25. PubMed ID: 24944269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
